drugset / Trial / NCT06862960
Ozanimod in Patients With Alzheimer's Disease
Phase 2
Not yet recruiting
40 enrolled
ChenXiaoChun
Fujian Medical University Union Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the benefits of ozanimod in patients with moderate Alzheimer's disease.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2027-06-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ozanimod | Small molecule | 0.92 mg | — |